Structure Therapeutics shares climbed 5.3% to $38.79 in late New York trading Thursday, with no new company release in the past two days. The move followed Eli Lilly’s report of strong weight-loss data for its obesity drug, which kept focus on the sector. Structure’s aleniglipron showed 16.3% placebo-adjusted mean weight loss at 44 weeks in Phase 2. Monashee Investment Management trimmed its stake in the first quarter, SEC filings show.